Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts

The Changing Natural History of Metastatic Prostate Cancer

(2013) Ajjai Alva et al.   CANCER JOURNAL

The Anti-CD19 Antibody-Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia

(2013) H. Carol et al.   CLINICAL CANCER RESEARCH

Novel Therapies for the Treatment of Advanced Prostate Cancer

(2013) J. M. Clarke et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

The Mutational Landscape of Prostate Cancer

(2013) Christopher E. Barbieri et al.   EUROPEAN UROLOGY

On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach

(2013) Nahor Haddish-Berhane et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Molecular Classification of Prostate Cancer Progression: Foundation for Marker-Driven Treatment of Prostate Cancer

(2013) C. J. Logothetis et al.   Cancer Discovery

Drug-conjugated antibodies for the treatment of cancer

(2012) John M. Lambert   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Progress in emerging therapies for advanced prostate cancer

(2012) Stéphane Oudard   CANCER TREATMENT REVIEWS

Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin

(2012) Dhaval K. Shah et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Long-term Tumor Regression Induced by an Antibody-Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells

(2012) P. Sapra et al.   MOLECULAR CANCER THERAPEUTICS

The mutational landscape of lethal castration-resistant prostate cancer

(2012) Catherine S. Grasso et al.   NATURE

Patient-derived tumour xenografts as models for oncology drug development

(2012) John J. Tentler et al.   Nature Reviews Clinical Oncology

Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma

(2012) Xiumei Zhao et al.   NEURO-ONCOLOGY

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic Mechanism and Efficacy of the Antibody-Drug Conjugate BAY 79-4620 Targeting Human Carbonic Anhydrase 9

(2011) H. M. Petrul et al.   MOLECULAR CANCER THERAPEUTICS

In Vitro and In Vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen

(2011) X. Wang et al.   MOLECULAR CANCER THERAPEUTICS

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

(2011) Yoko S DeRose et al.   NATURE MEDICINE

Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review

(2010) Ketao Jin et al.   Clinical & Translational Oncology

Antibody–drug conjugates: targeted drug delivery for cancer

(2010) Stephen C Alley et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity

(2009) S. C. Alley et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Establishment of Patient-Derived Non-Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers

(2008) I. Fichtner et al.   CLINICAL CANCER RESEARCH